Comparative Pharmacology
Head-to-head clinical analysis: ARIKAYCE KIT versus RIFABUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIKAYCE KIT versus RIFABUTIN.
ARIKAYCE KIT vs RIFABUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis.
Inhibits DNA-dependent RNA polymerase in susceptible bacteria, blocking RNA synthesis.
590 mg (contents of one kit) administered as inhalation via the Lamira Nebulizer System once daily.
300 mg orally once daily. For Mycobacterium avium complex (MAC) prophylaxis, 300 mg once daily. For active tuberculosis (in combination therapy), 5 mg/kg (up to 300 mg) orally once daily or 5 times weekly.
None Documented
None Documented
The terminal elimination half-life of amikacin from plasma is approximately 2-3 hours in patients with normal renal function. In the liposomal formulation (ARIKAYCE), after inhalation, the half-life in epithelial lining fluid is prolonged, with a terminal half-life of approximately 23 hours. Clinical context: accumulation may occur with renal impairment.
Clinical Note
moderateRifabutin + Digoxin
"The metabolism of Digoxin can be increased when combined with Rifabutin."
Clinical Note
moderateRifabutin + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Rifabutin."
Clinical Note
moderateRifabutin + Clobetasol propionate
"The serum concentration of Clobetasol propionate can be decreased when it is combined with Rifabutin."
Clinical Note
moderateRifabutin + Estrone sulfate
45 hours (range 32-67 hours) in adults; terminal elimination half-life decreases to 17 hours after repeated dosing due to autoinduction of metabolism.
Amikacin is primarily eliminated unchanged by glomerular filtration; renal excretion accounts for approximately 94-98% of the dose within 24 hours. Biliary/fecal elimination is minimal (<1%).
Renal (53% as unchanged drug and metabolites), fecal (30%), with biliary excretion contributing to enterohepatic recycling.
Category C
Category A/B
Antimycobacterial
Antimycobacterial
"The metabolism of Estrone sulfate can be increased when combined with Rifabutin."